probucol has been researched along with Hyperlipoproteinemia in 25 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 7.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 7.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Thirty five patients with cardiovascular diseases and hypercholesterolemia were treated with probucol and a low-fat diet for 12 to 50 months." | 7.66 | [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)]. ( Renais, J; Scebat, L, 1980) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 3.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 3.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Thirty five patients with cardiovascular diseases and hypercholesterolemia were treated with probucol and a low-fat diet for 12 to 50 months." | 3.66 | [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)]. ( Renais, J; Scebat, L, 1980) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Probucol is a drug with hypolipidemic effect from the group of diphenols." | 1.27 | [Clinical research on the hypolipidemic action of a probucol preparation]. ( Balabanski, L; Goranov, I; Kerekovska, M; Naumova, R, 1986) |
| "Large Achilles tendon xanthomas of the type found in severe familial hypercholesterolemia were the first manifestation of cholestanolosis (cerebrotendinous xanthomatosis) in our patient, an otherwise asymptomatic normolipidemic 21-year-old woman." | 1.27 | Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia. ( Cantin, M; Davignon, J; Lussier-Cacan, S; Nestruck, AC; Roy, CC; Sniderman, AD, 1986) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (56.00) | 18.7374 |
| 1990's | 10 (40.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donatelli, L | 1 |
| Bobkova, VI | 1 |
| Lokshina, LI | 1 |
| Sidakova, MM | 1 |
| Tananova, GV | 1 |
| Fomchenkov, SI | 1 |
| Atmeh, RF | 1 |
| Stewart, JM | 1 |
| Boag, DE | 1 |
| Packard, CJ | 1 |
| Lorimer, AR | 1 |
| Shepherd, J | 1 |
| Saunders, RN | 1 |
| Azarnoff, DL | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Scebat, L | 1 |
| Renais, J | 1 |
| Dujovne, CA | 1 |
| Harris, WS | 1 |
| Gerrond, LL | 1 |
| Fan, J | 1 |
| Muzio, F | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Tvorogova, MG | 1 |
| Lupanov, VP | 1 |
| Nuraliev, EIu | 1 |
| Zaĭtseva, TM | 2 |
| Kukharchuk, VV | 1 |
| Titov, VN | 2 |
| Toyota, Y | 1 |
| Yamamura, T | 1 |
| Miyake, Y | 1 |
| Yamamoto, A | 2 |
| Dalmau Serra, J | 1 |
| Hirano, T | 1 |
| Mamo, JC | 1 |
| Nagano, S | 1 |
| Sugisaki, T | 1 |
| Vogt, HB | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Murase, T | 1 |
| Hunninghake, DB | 1 |
| Saito, Y | 1 |
| Yoshida, S | 1 |
| Matsuzawa, Y | 1 |
| Yamashita, S | 1 |
| Funahashi, T | 1 |
| Tarui, S | 1 |
| Davignon, J | 2 |
| Blum, CB | 1 |
| Levy, RI | 2 |
| Naumova, R | 1 |
| Kerekovska, M | 1 |
| Goranov, I | 1 |
| Balabanski, L | 1 |
| Lussier-Cacan, S | 1 |
| Cantin, M | 1 |
| Roy, CC | 1 |
| Sniderman, AD | 1 |
| Nestruck, AC | 1 |
| Schaefer, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for probucol and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Pharmacology of probucol. I].
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra | 1984 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
Hyperlipoproteinemias: part IV. Drug regimens.
Topics: Anticholesteremic Agents; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Niacin; Probucol | 1991 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
1 trial available for probucol and Hyperlipoproteinemia
| Article | Year |
|---|---|
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
18 other studies available for probucol and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
Topics: Coronary Disease; Drug Evaluation; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipide | 1984 |
The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; | 1983 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)].
Topics: Adult; Aged; Anticoagulants; Cardiovascular Diseases; Cholesterol; Diuretics; Drug Interactions; Fem | 1980 |
Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
Topics: Antioxidants; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemias; Lipoprotei | 1994 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
[A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
Topics: Adult; Aged; Apolipoproteins; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relatio | 1998 |
Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia.
Topics: Adult; Bezafibrate; Female; Humans; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agent | 1999 |
[Drug therapy of hyperlipoproteinemias].
Topics: Adolescent; Child; Child, Preschool; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglut | 1991 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Hyperlipoproteinemia: classification and current problems].
Topics: Diet; Heptanoic Acids; Humans; Hyperlipoproteinemias; Lipoproteins; Naphthalenes; Pravastatin; Probu | 1990 |
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combinati | 1989 |
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |
[Clinical research on the hypolipidemic action of a probucol preparation].
Topics: Adult; Cholesterol; Drug Evaluation; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type | 1986 |
Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia.
Topics: Adult; Apolipoproteins B; Bile; Bile Acids and Salts; Cholesterol; Dietary Fats; Female; Humans; Hyp | 1986 |